Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway

Open access

Abstract

Background The prognosis of pancreatic cancer is poor and new treatment strategies are urgently needed. To identify non-cancer drugs that could be re-purposed for cancer, we investigated the association between the use of selected drugs and cancer-specific mortality in a nationwide cohort of pancreatic cancer patients. Material and methods The study is based on linkage between the Cancer Registry of Norway and the Norwegian Prescription Database, comprising 2614 pancreatic cancer patients diagnosed between 2007 and 2014. We evaluated the association between use at diagnosis of a pre-defined list of non-cancer drugs, including metformin, antihypertensives, and statins, and pancreatic cancer-specific mortality, using Cox regression. Patients were defined as users of a particular drug if it was prescribed before diagnosis, and the prescription covered the date of diagnosis. Results In total, 2096 (80.2%) patients died from pancreatic cancer; median survival was 6 months. Statin users (n = 621) had lower mortality (hazard ratio (HR): 0.86; 95% confidence interval (CI) 0.76–0.97) compared to non-users (n = 1993). This association was more pronounced (P-heterogeneity 0.062) in users of hydrophilic (n = 37, HR: 0.61; 95% CI 0.42–0.90) than lipophilic (n = 587, HR: 0.87; 95% CI 0.78–0.98) statins. An indication for lower mortality (HR: 0.85; 95% CI 0.69–1.05) was observed in users of non-selective beta-blockers (n = 113) compared to non-users (n = 2501). Notably, when compared to use…

Overview

Integrity signals

Registry

Crossref · 10.1080/0284186x.2021.1953136

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 55 · Cited by 22

Research works printed but not linked: 2

  1. Kheloussi S., 2018, US Pharm, 43, 22
  2. Li G, 2017, Int J Epidemiol, 46, 746

Metadata

Authors
Støer, N. C., Bouche, G., Pantziarka, P., Sloan, E. K., Andreassen, B. K., & Botteri, E.
Affiliations
  • Cancer Registry of Norway (NO)
  • Anticancer Fund (BE)
  • Peter MacCallum Cancer Centre (AU)
Corresponding author
Støer, Nathalie C.
Venue
Acta Oncologica
Published
2021-08-02
Volume
60
Issue
9
Pages
1146-1153
ISSN
  • 0284-186X (ISSN-L)
  • 1651-226X
OpenAlex
W3192882316
Cited by
22
References
55
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 3
FWCI
1.18
Type
journal article
Language
en
Open access
Locations
  • Acta Oncologica (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
pancreatic ductal adenocarcinoma, cancer-specific mortality, statins, non-selective beta-blockers, metformin, antihypertensive drugs, drug repurposing, cancer prognosis, hydrophilic statins, survival, prescription drug use, Norwegian Prescription Database, drug-drug interactions
MeSH terms
Adenocarcinoma, Humans, Metformin, Pancreatic Neoplasms, Registries, Cohort Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. https://app.cochat.ai/papers/10.1080/0284186x.2021.1953136
The paper
Støer, N. C., Bouche, G., Pantziarka, P., Sloan, E. K., Andreassen, B. K., & Botteri, E. (2021). Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. Acta Oncologica. https://doi.org/10.1080/0284186x.2021.1953136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.